Be very afraid: some info from AGPH site for the basics of yet another one of their "blockbusters". You never know when the phase I results will be released, of course they really have already been done in Europe, very positive:
"AG3340 Matrix Metalloprotease (MMP) Inhibitor for Cancer and Arthritis
AG3340
Matrix metalloprotease inhibitor for Cancer and Arthritis
Development status:
Clinical: Phase I
Independent research has shown MMPs to be involved in many disease states. Within the cancer field, certain MMPs have been associated with tumor growth, the metastasis of tumor cells to secondary sites within the body and the growth of new blood vessels (angiogenesis), through which tumor cells obtain nutrients and growth factors. The Company believes that MMPs thus represent a new opportunity for the discovery of novel agents which prevent tumor cell growth (tumoristatic). The Company further believes that orally active inhibitors of certain combinations of MMPs, but not of all MMPs, are most likely to have the optimal safety and efficacy profiles of superior tumoristatic agents.
In addition to their role in the growth and metastasis of solid tumors, MMPs display high levels of enzymatic activity in such degenerative diseases as rheumatoid arthritis and osteoarthritis. Certain members of the MMP family are associated most closely with these disease states and, Agouron believes, offer targets for orally active drugs with potential for minimal toxicity. If successfully developed, Agouron believes such selective inhibitors of certain MMPs have the potential to interrupt the progression of arthritic disease itself rather than just to treat the symptoms.
AG3340 is currently being developed by Agouron in collaboration with Hoffmann-La Roche Inc., Nutley, N.J. Under terms of the collaboration, Roche will bear 80% of development costs of AG3340 and will lead commercialization of the drug outside of North America subject to payment of royalties to Agouron. Roche and Agouron will co-promote AG3340 in North America and will share equally in profits derived from North American sales of the drug."
How about discussing the other 95% of this biotech, besides just one of their "bockbuster" drugs. |
